Since the glycan profile of a cancer cell is a major determinant of Gal-3 binding activity [20], and because GCNT2 expression was shown to influence melanoma cell behavior by controlling its growth, signaling, and survival activities [8], we investigated the possibility that GCNT2/I-branching functions as a putative inhibitor of Gal-3 binding activity. The gene discussed is LGALS3; the disease is cancer.